Società Carbylan Therapeutics Inc Nasdaq
Azioni
US1413841073
Prodotti farmaceutici
Attività
Dirigenti
Dirigenti | Titolo | Età | Da |
---|---|---|---|
Ed Feener
FOU | Founder | 64 | 26/03/04 |
Ben Palleiko
CEO | Chief Executive Officer | 58 | 01/08/16 |
Paul Audhya
CTO | Chief Tech/Sci/R&D Officer | 51 | 03/05/21 |
Ryan Baker
IRC | Investor Relations Contact | - | 01/05/23 |
Nicole Sweeny
PRN | Corporate Officer/Principal | 49 | 25/07/23 |
Christopher Yea
PRN | Corporate Officer/Principal | 61 | 01/11/16 |
Mike Smith
PRN | Corporate Officer/Principal | - | 01/02/16 |
Rachel Morten
LAW | General Counsel | - | 01/01/16 |
Amministratori
Amministratori | Titolo | Età | Da |
---|---|---|---|
Brian Pereira
CHM | Chairman | 65 | 01/02/19 |
Ben Palleiko
CEO | Chief Executive Officer | 58 | 01/08/16 |
Albert Cha
BRD | Director/Board Member | 51 | 01/01/16 |
Edward Unkart
BRD | Director/Board Member | 74 | 01/12/14 |
Nancy Stuart
BRD | Director/Board Member | 65 | 18/03/21 |
Patrick Treanor
BRD | Director/Board Member | - | 26/05/22 |
Classe di azioni
Voto | Quantità | Flottante | Autocontrollo | Flottante totale | |
---|---|---|---|---|---|
Azione A | 1 | 42 188 296 | 41 670 541 ( 98,77 %) | 0 | 98,77 % |
Coordinate società
KalVista Pharmaceuticals, Inc.
55 Cambridge Parkway Suite 901 East
02142, Cambridge
+857 999 0075
http://www.kalvista.comSettore
Variaz. 1 gen. | Capi. | |
---|---|---|
-2,29% | 89,87 Mrd | |
-3,95% | 37,57 Mrd | |
-13,07% | 32,75 Mrd | |
+63,05% | 26,47 Mrd | |
-22,14% | 14,25 Mrd | |
-7,96% | 12,99 Mrd | |
-9,33% | 11,93 Mrd | |
-46,33% | 10,84 Mrd | |
+5,77% | 9,11 Mrd |